Treatment of Erectile Dysfunction in Type 2 Diabetic Men
Background. One of the most frequent complications of diabetes in men is erectile dysfunction. Phosphodiesterase-5 inhibitors (IPDE-5): sildenafil, vardenafil and tadalafil are the drugs of choice for the treatment of erectile dysfunction. Objective. To study the effectiveness and safety of treatment of erectile dysfunction with inhibitor of phosphodiesterase 5 in type 2 diabetic men. Material and methods. The study involved 89 men aged 39–69 years old. Рatients with type 2 diabetes mellitus and erectile dysfunction with diabetes duration of 1–12 years were examined in a state of diabetes mellitus compensation (average glycated hemoglobin 7.3 ± 1.1 %). Sildenafil 100 mg on demand before coitus during 12 weeks led to the significant growth rate of domain of «Erectile function» on 10.54 score. Sildenafil was effective in 76.2 % of patients. Increment of such parameter as erectile function during tadalafil treatment was 9.81 scores. Efficacy of tadalafil was 73.1 %. Application of vardenafil led to the improvement of erectile function to an average of 25.22 ± 1.80 scores. Efficacy of vardenafil in our patients was 76.2 %. Conclusions. The study confirmed the high efficiency of three IPDE-5 as the first-line drugs for the treatment of erectile dysfunction in men with diabetes. All three drugs were used in maximum doses, as lower doses are not always effective enough. All patients with reduced blood levels of total testosterone should receive replacement therapy to achieve levels of testosterone within the normal hormone fluctuations. Further study of the effects IPDE-5 in type 2 diabetic men are necessary to improve their effectiveness.
Väätäinen S, Keinänen-Kiukaanniemi S, Saramies J. Quality of life along the diabetes continuum: A cross-sectional view of health-related quality of life and general health status in middle-aged and older Finns. Qual Life Res. 2014; 23: 935-44.
Porojan M, Poanta L, Dumitrascu DL. Assessing health related quality of life in diabetic patients. Rom J Intern Med. 2012; 50: 27-31.
Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6: 1232-47.
De Berardis G, Franciosi M, Belfiglio M. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care. 2002; 25: 84-91.
Yamaguchi Y, Kumamoto Y. Etiological analysis of male diabetic erectile dysfunction with particular emphasis on findings of vascular and neurological examinations. Nippon Hinyokika Gakkai Zasshi. 1994; 85: 1474-83.
Corona J, Mannucci E, Petrone L. NCEP-ATPIII – defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J.Sex.Med. 2007; 4: 1038-45.
Montorsi F, Salonia A, Deho F. Pharmalogical management of erectile dysfunction. B.J.U. 2003; 91: 446-54.
The Real-Life Safety and Efficacy of Varenafil (REALISE) – Subgroup analysis of patients with cardiovascular diseases, diabetes mellitus or hypertension. J.Sex. Med. 2006; 3(Suppl.3): 25.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019